Dossier - Page 1 - FirstWord Reports

Learn More Real World Data for Orphan Drugs: Meeting the Data Analysis Challenge

Creating meaningful insights from diverse data sources The explosion in real-world data (RWD) from digital platforms is creating new insights into the understanding of rare diseases and patient experiences. The value...

Compare
Learn More The Future of Decentralised Clinical Trials

COVID-19 has driven innovation in clinical trials, but what happens next and how can pharma prepare? Pre-pandemic many companies were curious to explore the potential of decentralized clinical trials (DCTs), but now see...

Compare
Learn More Trends in KOL Experience Management [2020]

Is your MSL team delivering an outstanding KOL experience? KOL support and insights are critical to pharma, and MSLs are charged with delivering a service that keeps them fully informed and engaged. But how do you...

Compare
Learn More Pricing and Reimbursement in Neurology: Payer Views [2020]

Understanding payer challenges in Multiple Sclerosis, Epilepsy, Migraine and Neurodegenerative disease Despite wide unmet need across a number of neurological conditions, no really high impact breakthrough therapies...

Compare
Learn More Virtual Medical Conferences: The new normal?

Is the virtual medical conference here to stay? The crowded world of medical conferences was already ripe for change when the COVID-19 pandemic hit. Conference organizers responded quickly, rapidly accelerating their...

Compare
Learn More Remote Patient Monitoring: Pharma’s challenge and opportunity

Lessons for pharma as remote patient monitoring drives fundamental change in disease prevention and management. Accelerated by COVID-19, use of remote patient monitoring (RPM) technology has grown rapidly. Increasingly...

Compare
Learn More Value-based Healthcare in a Digital World [2020]

Accelerated use of digital technology challenges pharma to rethink its approach COVID-19 has radically increased the use of digital technology by patients and HCPs but how does that play into the trend to value-based...

Compare
Learn More Orphan Drugs: Benchmarking Commercial Models [2020]

What are the essential factors for orphan drug success? Several orphan drugs have proven to be commercial winners, so what are the key ingredients for success in 2020? For example, as the sector has evolved the power...

Compare
Learn More Trends in Digital Pharma Marketing (2020)

How has COVID-19 impacted pharma digital marketing activity—now and for the future? The effects of coronavirus on pharma marketing budgets, priorities and actions cannot be ignored. During the pandemic, pharma...

Compare
Learn More MSL-KOL Engagement [2020]

Maintaining and growing KOL relationships in pandemic lockdown At a stroke, the COVID-19 pandemic shut down MSL's principal KOL engagement channels. With face-to-face interactions on hold, MSLs have turned to...

Compare
Learn More The Rise of ICER – The Payer Perspective

Payers reveal where ICER is really impacting pharma/payer relations How is the Institute for Clinical and Economic Review (ICER) influencing payer behavior? ICER's evidence and price benchmarking data are valued by...

Compare
Learn More The State of Pharma Digital Transformation 2020

How far has pharma come, and what does it still need to do, to realize the full benefits of digital technology across its business? The COVID-19 pandemic may have spurred rapid expansion in the use of digital tools but...

Compare
Learn More Telemedicine’s Move into the Mainstream

COVID-19 accelerated uptake of telemedicine is rapidly transforming healthcare delivery Telemedicine is one major success story of the pandemic. Barriers previously hindering widespread adoption of telehealth practices...

Compare
Learn More Smart Pharma Sales: How Digital is Reinventing the Process

Post COVID-19, pharma's opportunity is to build on the impact of digital technology to revolutionize its sales practice and engagement strategies The COVID-19 pandemic has radically reshaped how pharma does sales and...

Compare
Learn More Engaging with ICER: Lessons and insights for pharma

ICER is here to stay so how best can industry engage for its benefit? The Institute for Clinical and Economic Review (ICER) is gaining a growing reputation with US payers. While ICER's drug assessments are advisory, and...

Compare
Learn More Digital Health and the Management of Chronic Disease

Essential strategies for developing next phase digital health solutions The COVID-19 pandemic has accelerated and elevated the role of digital health and could serve as a turning point for digital platforms to become...

Compare
Learn More COVID-19 Implications for pharma: US payer insights

What are the implications for pharma as COVID-19 forces fundamental change in US payer practice and policy? The COVID-19 pandemic has created a unique set of challenges for US payers. In the short-term emergency...

Compare
Learn More Measuring Digital Success in Pharma: Essential KPIs

Which KPI's should pharma be using to assess the success of its digital technology investments? The Covid-19 pandemic is fundamentally changing working practice and driving immediate expansion of digital solutions. But...

Compare
Learn More Biosimilars: US Payer Insights 2020

What do payers see as unlocking the sluggish US biosimilar market? Despite the availability of biosimilar versions of Avastin, Herceptin and Rituxan, payers are not pleased with the development within this sector...

Compare
Learn More Digital Biomarkers: Pharma’s clinical development future?

Assessing digital biomarker applications that could radically impact pharma's clinical research practice By precisely and continuously measuring disease symptoms, digital biomarkers can allow pharma to establish valid...

Compare

Browse by